Pierre Formstecher
Overview
Explore the profile of Pierre Formstecher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1081
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corvaisier M, Bauzone M, Corfiotti F, Renaud F, El Amrani M, Monte D, et al.
Oncotarget
. 2016 Aug;
7(35):56699-56712.
PMID: 27527859
Our aim was to decipher the role and clinical relevance of the YAP/TAZ transcriptional coactivators in the regulation of the proliferation/quiescence balance in human colon cancer cells (CCC) and survival...
2.
Touil Y, Segard P, Ostyn P, Begard S, Aspord C, El Machhour R, et al.
Sci Rep
. 2016 Jul;
6:30405.
PMID: 27465291
Metastatic cancer relapses following the reactivation of dormant, disseminated tumour cells; however, the cells and factors involved in this reactivation are just beginning to be identified. Using an immunotherapy-based syngeneic...
3.
Chabannon C, Bougnoux P, Favre G, Formstecher P, Laurent-Puig P, Oudet P, et al.
Med Sci (Paris)
. 2014 Oct;
30(10):925.
PMID: 25311029
The authors, all in charge of the administration of one of the 7 French Cancéropôles, reply to the article authored by Audrey Vézian, and -provide an alternative and more supportive...
4.
Ostyn P, El Machhour R, Begard S, Kotecki N, Vandomme J, Flamenco P, et al.
Cell Commun Signal
. 2014 Sep;
12:52.
PMID: 25223735
Background: It is well established that inflammation promotes cancer, including melanoma, although the exact mechanisms involved are less known. In this study, we tested the hypothesis that inflammatory factors affect...
5.
Ballot C, Martoriati A, Jendoubi M, Buche S, Formstecher P, Mortier L, et al.
Mar Drugs
. 2014 Jan;
12(2):779-98.
PMID: 24473175
Lamellarin D (LamD) is a marine alkaloid with broad spectrum antitumor activities. Multiple intracellular targets of LamD, which affect cancer cell growth and induce apoptosis, have been identified. These include...
6.
Touil Y, Igoudjil W, Corvaisier M, Dessein A, Vandomme J, Monte D, et al.
Clin Cancer Res
. 2013 Dec;
20(4):837-46.
PMID: 24323901
Purpose: Metastasis and drug resistance are the major limitations in the survival and management of patients with cancer. This study aimed to identify the mechanisms underlying HT29 colon cancer cell...
7.
Vandomme J, Touil Y, Ostyn P, Olejnik C, Flamenco P, El Machhour R, et al.
Stem Cells Dev
. 2013 Nov;
23(8):839-51.
PMID: 24266654
Dental pulp stem cells (DPSCs) remain quiescent until activated in response to severe dental pulp damage. Once activated, they exit quiescence and enter regenerative odontogenesis, producing reparative dentin. The factors...
8.
Dezitter X, Fagart J, Taront S, Fay M, Masselot B, Hetuin D, et al.
Mol Pharmacol
. 2013 Nov;
85(2):226-36.
PMID: 24225022
There is a therapeutic need for glucocorticoid receptor (GR) ligands that distinguish between the transrepression and transactivation activity of the GR, the later thought to be responsible for side effects....
9.
Corazao-Rozas P, Guerreschi P, Jendoubi M, Andre F, Jonneaux A, Scalbert C, et al.
Oncotarget
. 2013 Oct;
4(11):1986-98.
PMID: 24161908
Vemurafenib/PLX4032, a selective inhibitor of mutant BRAFV600E, constitutes a paradigm shift in melanoma therapy. Unfortunately, acquired resistance, which unavoidably occurs, represents one major limitation to clinical responses. Recent studies have...
10.
Guerreschi P, Scalbert C, Qassemyar A, Kluza J, Ravasi L, Huglo D, et al.
Melanoma Res
. 2013 Jul;
23(5):373-80.
PMID: 23852164
Recently, the BRAF V600 inhibitor, vemurafenib, has revolutionized the therapeutic management of metastatic melanoma. However, adverse effects and the onset of resistance are frequently observed, limiting the efficacy of this...